MENU
+Compare
CYCC
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$0.24
Change
-$0.01 (-4.00%)
Capitalization
84.11M

CYCC Cyclacel Pharmaceuticals Inc. Forecast, Technical & Fundamental Analysis

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases... Show more

Industry: #Biotechnology
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CYCC with price predictions
Jul 03, 2025

Momentum Indicator for CYCC turns negative, indicating new downward trend

CYCC saw its Momentum Indicator move below the 0 level on June 27, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In of the 78 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CYCC entered a downward trend on June 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for CYCC just turned positive on June 17, 2025. Looking at past instances where CYCC's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCC advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

CYCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.473) is normal, around the industry mean (16.672). P/E Ratio (0.082) is within average values for comparable stocks, (58.456). CYCC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. CYCC's P/S Ratio (3333.333) is very high in comparison to the industry average of (269.644).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CYCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CYCC is expected to report earnings to rise 4,033.00% to -41 cents per share on March 27

Cyclacel Pharmaceuticals Inc. CYCC Stock Earnings Reports
Q4'23
Est.
$-0.41
Q1'25
Beat
by $0.28
Q4'24
Beat
by $5.75
Q3'23
Missed
by $0.13
Q2'23
Beat
by $0.06
The last earnings report on May 14 showed earnings per share of 0 cents, beating the estimate of -28 cents. With 2.59M shares outstanding, the current market capitalization sits at 84.11M.
A.I. Advisor
published General Information

General Information

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCHEY17.41N/A
N/A
Beach Energy Ltd.
CAWW0.89N/A
N/A
CCA Industries, Inc.
CDGXF0.03N/A
N/A
China Dongxiang Group Co., Ltd.
NEXPF6.09N/A
N/A
NEXI S.P.A.
AMTPQ0.01N/A
N/A
Ameritrans Capital Corp.

CYCC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with MIRM. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
-4.80%
MIRM - CYCC
36%
Loosely correlated
+2.46%
ORMP - CYCC
30%
Poorly correlated
+0.93%
IMMP - CYCC
27%
Poorly correlated
+1.18%
RNAC - CYCC
26%
Poorly correlated
-1.41%
ICCC - CYCC
26%
Poorly correlated
+0.08%
More